Chinese expert consensus on neoadjuvant and conversion therapies for hepatocellular carcinoma

Table 1 Analysis of surgical data of 10966 patients with primary hepatocellular carcinoma

Stages and criteria	n (%)	Overall survival					Tumor recurrence
		Median time (mo)	1-yr survival rate (%)	3-yr survival rate (%)	5-yr survival rate (%)	10-yr survival rate (%)	Median time (mo)	1-yr recurrence rate (%)	2-yr recurrence rate (%)	3-yr recurrence rate (%)	5-yr recurrence rate (%)
First round of hepatectomy for HCC	2592	79.4	87.2	71.0	59.1	40.4	36.1	31.8	43.5	9.9	60.7
Stages Ia-IIIa	2549	82.3	88.1	71.9	60.0	41.0	37.0	31.0	42.9	49.3	60.3
Ia	1175	-	96.5	87.5	77.2	55.9	67.2	15.0	27.7	34.1	45.9
Ib	635	79.4	88.2	73.5	62.5	37.0	34.1	32.4	43.7	51.8	63.4
IIa	205	43.5	89.8	56.0	40.8	27.2	15.7	45.7	59.8	65.5	84.3
IIb	119	38.0	83.6	55.3	37.4	23.2	10.0	55.9	67.7	74.0	80.1
IIIa	415	21.9	65.1	38.2	23.8	16.0	7.9	59.9	69.8	73.8	80.2
IIIb	43	8.7	34.1	15.8	0	0	3.9	77.1	77.1	82.8	-

Overall survival and tumor recurrence of patients with different stages of hepatocellular carcinoma after undergoing hepatectomy[8]. Stages and criteria; overall survival; tumor recurrence; n; median time (months); 1-yr survival rate (%); 3-yr survival rate (%); 5-yr survival rate (%); 10-yr survival rate (%); median time (months); 1-yr recurrence rate (%); 2-yr recurrence rate (%); 3-yr recurrence rate (%); 5-yr recurrence rate (%); first round of hepatectomy for hepatocellular carcinoma; stages Ia-IIIa. HCC: Hepatocellular carcinoma.